News 2017-04-03T22:53:35+00:00

Verona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market

April 27, 2017, LONDON - Verona Pharma plc (AIM: VRP) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announces today the pricing of its global offering of an aggregate of 47,399,001 new ordinary shares, comprising 5,768,000 American Depositary Shares ("ADSs") at a price of $13.50 per ADS and 1,255,001 ordinary shares at a price of £1.32 per ordinary share, [...]

April 27th, 2017|

Proton Partners International Annouces New Cancer Centre In North West

Liverpool, 15th March 2017: Proton Partners International has today announced plans to build a new £35 million cancer treatment centre in Liverpool. The cancer centre will be built in the new £1 billion Paddington Village, part of Liverpool’s Knowledge Quarter (KQ). This will be one of four centres built by Proton Partners International in the UK and will make the company the world’s largest developer [...]

March 15th, 2017|

Proton Partners International Announces the Rutherford Cancer Centres

22 February 2017: Proton Partners International has announced today it is to name its clinics The Rutherford Cancer Centres. The Rutherford Cancer Centres will offer patients a comprehensive range of cancer treatments and, from 2018, will be the first in the UK to offer high energy proton beam therapy. The oncology centres have been named to reflect the renowned scientist Ernest Rutherford’s contribution in identifying [...]

February 22nd, 2017|

Apitope Announces Positive ATX-MS-1467 Phase IIa Data in Relapsing Multiple Sclerosis

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of ATX-MS-1467 in 19 patients with relapsing [...]

February 21st, 2017|

Arthurian life sciences statement on reneuron stroke study results

Arthurian Life Sciences today welcomed the ‘highly encouraging’ findings of a significant clinical trial by ReNeuron, a global leader in the development of cell-based therapeutics. The PISCES II trial monitored improvement in arm movement as measured by the ARAT sub-test number two. The aim was to achieve discernible change within three months in two of the 21 patients receiving treatment. Three patients registered improvement over [...]

December 5th, 2016|